Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Hou

Showing results (941-950 of 953) with videos related to

Pageof 96
Sort By:
Hepatology International|January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.
Journal of Clinical and Translational Hepatology|September 15, 2025
Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical ModelRong Fan, Ya-Ru Shi, Lei Chen, et al.
Journal of Gastroenterology and Hepatology|January 31, 2018
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in ChinaLai Wei, Qing Xie, Jin Lin Hou, et al.
Hepatology International|August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.
Zoological Research|March 30, 2023
Cell atlas of CCl <sub>4</sub>-induced progressive liver fibrosis reveals stage-specific responsesPeng-Cheng Guo, Jing Zuo, Ke-Ke Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Plos One|June 9, 2016
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataGuo-Feng Chen, Lai Wei, Jing Chen, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trialLai Wei, Seng Gee Lim, Qing Xie, et al.
Ebiomedicine|January 7, 2024
Cell-free DNA testing for early hepatocellular carcinoma surveillanceLei Chen, Tong Wu, Rong Fan, et al.
Journal of Hematology & Oncology|January 4, 2023
The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosisTong Wu, Rong Fan, Jian Bai, et al.
Pageof 96

Showing results (941-950 of 953) with videos related to

Sort By:
Pageof 96
Hepatology International|January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.
Journal of Clinical and Translational Hepatology|September 15, 2025
Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical ModelRong Fan, Ya-Ru Shi, Lei Chen, et al.
Journal of Gastroenterology and Hepatology|January 31, 2018
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in ChinaLai Wei, Qing Xie, Jin Lin Hou, et al.
Hepatology International|August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.
Zoological Research|March 30, 2023
Cell atlas of CCl <sub>4</sub>-induced progressive liver fibrosis reveals stage-specific responsesPeng-Cheng Guo, Jing Zuo, Ke-Ke Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Plos One|June 9, 2016
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataGuo-Feng Chen, Lai Wei, Jing Chen, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trialLai Wei, Seng Gee Lim, Qing Xie, et al.
Ebiomedicine|January 7, 2024
Cell-free DNA testing for early hepatocellular carcinoma surveillanceLei Chen, Tong Wu, Rong Fan, et al.
Journal of Hematology & Oncology|January 4, 2023
The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosisTong Wu, Rong Fan, Jian Bai, et al.
Pageof 96